Table 3 Medication in JDM patients total, < 20y and ≥ 20y

Prednisolone or DMARD at FU, n

17 (28.8)

13 (46.4)

4 (12.9)

0.004

Prednisolone at FU (yes/no), n

10 (16.9)

7 (12.5)

3 (4.8)

0.13

Methotrexat at FU, n

10 (8.5)

9 (16.1)

1 (1.6)

0.01

Prednisolone during disease course, n

51 (86.4)

26 (92.9)

25 (80.6)

0.17

Methotrexat during disease course, n

30 (50.8)

18 (64.3)

12 (38.7)

0.05

Prednisolone medication time, months

31 (14.0–57.0)

24.5 (13.3–35.0)

48.0 (16.0–85.0)

0.05

Cumulative prednisolone total, g

7.90 (30.00–79.23)

6.14 (0.00–16.23)

9.68 (0.00–79.23)

0.03

Cumulative prednisolone 6 m after diagnosis^a, g (n = 58/28/31)

2.76 (0.00–6.65)

2.89 (0.00–6.38)

2.61 (0.00–6.65)

0.60

Cumulative prednisolone 2 y after diagnosis, g

4.81 (0.00–0-16.50)

4.26 (0.00–9.80)

6.75 (0.00–16.49)

0.19

Cumulative prednisolone 6.5 y after diagnosis, g

7.35 (0.00–28.39)

6.14 (0.00–12.64)

9.43 (0.00–28.40)

0.18

Time from last prednisolone dose to FU, months

67.0 (0–162.0)

42.7 (0–67.8)

145.0 (0–253.0)

0.002